Little attention has been dedicated to assessing the economics of the choice of volatile agents in anaesthesia, and there are few studies evaluating the long-term trends and costs of volatile agent use 1-3 . Anaesthetic drugs account for up to 6% of total pharmacy expenditure and volatile agents can account for up to 20% of this budget 3 . These costs are determined by the choice of volatile agent, rate of fresh gas flow, vaporiser dial setting and number of volatile agent anaesthetic hours.
Austin/163), we reviewed the number and cost of bottles of isoflurane, sevoflurane and desflurane ordered across 65 metropolitan and regional public hospitals in the state of Victoria, Australia, from 2005 to 2011. The descriptors of the state of Victoria 5 are as follows: Victoria is a state of Australia with the second largest population at 5.6 million. Approximately 75% of the population lives in the greater Melbourne (capital) metropolitan area. Twenty-five percent live in regional Victoria. Our data captured 24 out of the 26 major metropolitan public hospitals and 18 out of the 19 major regional public hospitals which are used to determine key performance indicators in Victoria's health service delivery. The other 23 minor public hospitals we captured were from regional Victoria. Acquisition costs were calculated in Australian dollars.
Audit data were obtained via IMS Health, a global company who track pharmaceutical sales activity. Data was presented for each hospital on a yearly basis. In order to correct for annual inflation over this time period, the annual volatile agent acquisition cost was adjusted based on the Australian Consumer Price Index 6 . As our interest was in the overall pattern of usage by Australian anaesthetists, we did not look at the number of cases or general anaesthesia hours performed each year. To adjust for the increase dworkload over time, we pooled the number of bottles of isoflurane, sevoflurane and desflurane ordered from every hospital and converted them into relative proportions of each other on a yearly basis. We did the same for acquisition costs.
To measure the environmental cost, we calculated the yearly greenhouse gas emissions measured through the 100-year global warming potential index for each volatile agent (Table 1 ) expressed as carbon dioxide equivalents per kilogram for each bottle of volatile agent. This was corrected for hepatic metabolism: sevoflurane at 3.5%, isoflurane at 0.2% and desflurane at 0.02%.
Statistical analyses
A computerised statistical package (Small Stata 12.0 for Mac, College Station, Texas, USA) was used for time series data analysis using an autoregressive integrated moving average model (Box-Jenkins). Proportion and ratio data points were plotted to determine if the relationship was linear, exponential or logarithmic. If the relationship was non-linear, the data points underwent natural logarithmic transformation. All natural and transformed time series data points were rendered stationary by firstorder differencing. Autocorrelation functions and partial autocorrelation functions were then examined to determine the model. A first-order autoregressive model was deemed the most appropriate. Bottles and costs were reported with slope coefficients and corresponding 99% confidence intervals (CI). Proportions and ratios, depending on their relationship, were reported with slope coefficients, exponential or logarithmic factors along with their corresponding 99% CI.
RESULTS
In Victoria, the aggregate inflation-adjusted expenditure on inhalational agents for the time period 2005 to 2011 was $39,209,878. Table 2 shows the average inflation-adjusted acquisition cost per bottle of these agents from 2005 to 2011. Totals, in volatile agent bottles ordered and costs, are shown in Figures 1 and 2 respectively. Time series analysis showed that bottles of isoflurane ordered decreased by 419/year (99% CI: -603 to -235) and costs decreased by $56,017/year (99% CI: -$93,243 to -$18,791). Bottles of sevoflurane increased by 1,330/year (99% CI: 1,141 to 1,519) and costs decreased by $423,3573/year (99% CI: -$720,030 to -112,783). Bottles of desflurane increased by 726/ year (99% CI: 288 to 1,164) and costs increased by $171,578/year (99% CI: $136,951 to $206,205). Correcting for workload, proportional bottles and costs (%) are shown as trend lines in Figures 1 and 2. Isoflurane ordered exponentially decayed by a factor of -0.331/year (99% CI: -0.349 to -0.312) and proport-ional costs decreased by an exponent factor of -0.292/year (99% CI: -0.330 to -0.254). Proportional bottles of sevoflurane ordered exponentially grew by a factor of 0.007/year (99% CI: 0.001 to 0.014) and proportional costs exponentially decayed by a factor Sevoflurane consistently remained the most common volatile agent used during this period, ranging from 74% in 2005 to 77% in 2011. Its proportional yearly cost dropped from 88% to 69%. This reflected the 64% reduction in its price per bottle and the proportional rise in costs associated with desflurane's increased usage and price per bottle.
The total amount of calculated greenhouse gas emissions released into the atmosphere over this seven-year period was 37,000 tonnes of carbon dioxide equivalents, with isoflurane contributing 6%, sevoflurane 17% and desflurane 77% of this total. The yearly individual contributions from each volatile agent are shown in Figure 3 . Proportionately, isoflurane was responsible for 22% of total yearly emissions in 2005, dropping to 2% in 2011. In contrast, desflurane accounted for 55% in 2005, and 81% in 2011.
DISCUSSION
We performed a pharmaco-economic study evaluating the current trend, pattern and cost of volatile agent use in Victoria over a seven-year period. We found that despite a 33% inflation-adjusted cost reduction in isoflurane, its annual use decreased. In contrast, over the same period, desflurane use more than doubled despite a 9% inflation-adjusted cost rise. Use of sevoflurane increased only marginally, despite a 64% inflation-adjusted cost reduction following its patent expiration in 2005.
On these current trends, isoflurane is no longer being used in the majority of Victorian public hospitals with sevoflurane and desflurane remaining as the primary volatile agents in most Victorian public hospitals, with sevoflurane and desflurane utilised at a ratio of 2.2 to 1, and costs at 0.8 to 1. This multicentre audit of public hospitals in the second most populous Australian state confirms previous findings from single institutions in both Australia 1 and New Zealand 8 .
There are several possible factors contributing to this practice trend. Firstly, there is a perception that sevoflurane and desflurane consistently reduce the time to extubation compared to isoflurane, improving workflow and reducing theatre labour costs; secondly, there appears to be a 'culture shift' away from using isoflurane making it an 'unfamiliar' drug in many institutions, particularly amongst trainees; thirdly, many modern anaesthesia workstations only allow one or two volatile agent modules to be seated, with many anaesthetists choosing sevoflurane and/or desflurane as their preferred agents; and finally, there is little consideration of the environmental impact of volatile agent use.
The perception that sevoflurane or desflurane compared to isoflurane consistently and significantly reduces the average and variability of time to extubation for all types of general anaesthetics is a misconception. In fact, the degree of difference appears to be affected not by the choice of volatile agent but by the choice of airway: laryngeal mask airway (LMA) versus endotracheal tube (ETT) 9 .
Choice of airway appears to be a surrogate marker of length of surgery, with LMAs associated with shorter surgical procedures than ETTs 10 . In the meta-analysis by Agoliati et al, the percentage reductions in time to extubation of LMAs relative to isoflurane when using desflurane is 18% (95% CI 9.2% to 26%) and when using sevoflurane is 9% (95% CI -15% to 28%) 9 . Analysing the studies included in the meta-analysis, the average surgical time for using an LMA is 45 minutes compared to 146 minutes with an ETT. Therefore, for a given percentage reduction, the absolute reduction in time to extubation for an anaesthetic using an LMA will be clinically less significant compared to a longer anaesthetic using an ETT. In addition, the majority of LMA cases in Australia can be recovered in the post anaesthesia care unit, negating the need for faster LMA extubation times to reduce operating room labour costs. Sevoflurane and desflurane should therefore only be reserved for longer cases in preference to isoflurane, where the absolute differences in extubation times are larger 10, 11 . Other factors that need to be explored are the influence of nitrous oxide and bispectral index on the average and variability of time to extubation. Use of nitrous oxide has been shown to increase the speed of emergence from sevoflurane anaesthesia by 17% 12 . However, despite its pharmacokinetic advantage, low acquisition cost and volatile agent-sparing effects, nitrous oxide is associated with significant complications 13 and greenhouse gas emissions 14 affecting its cost-benefit ratio; thereby limiting its use to low-risk groups only. Time to extubation and volatile requirements may also be reduced with bispectral index. A meta-analysis by Punjasawadwong et al suggests a reduction of 2.58 minutes (95% CI -3.50 to -1.67) with sevoflurane anaesthesia 15 . Considerations here would need to include a comparison to surgical time to know if the relative difference is clinically significant, as well as the cost of the module and disposables (sensor cost is $18). Given the average cost per minimum alveolar concentration hour at 1 l/minute of desflurane is currently $20 more than sevoflurane, it would make it economically viable to use bispectral index in cases at risk of prolonged time to extubation.
Utilisation and environmental costs of volatile agents can be further broken down into: (i) acquisition cost and 100-year global warming potential per kg respectively; (ii) minimum alveolar concentration; and (iii) fresh gas flow rate. In this regard, desflurane's minimum alveolar concentration is important because the fraction delivered is three times that of isoflurane, and 2.4 times that of sevoflurane. Taking into account desflurane's comparatively high acquisition cost (Table 2 ) and the fact that it is approximately five times more pollutant than isoflurane and 20 times more pollutant than sevoflurane 14, 16 , the consequences of this are a disproportionate share in costs (30%) and environmental pollution (81%) in 2011 compared to bottles ordered (21%). A tangible price can be placed on this pollution through the use of a carbon price. In 2012 to 2013, the price of carbon in Australia was set at $23 per tonne of carbon dioxide equivalents 17 . This increases the cost of a bottle of desflurane by $20.50, isoflurane by $4.40 and sevoflurane by $1.10.
In conclusion, despite significant acquisition cost reductions in isoflurane, its annual use in Victorian public hospitals continues to decrease. The use of sevoflurane is increasing, albeit only marginally. However, the use of desflurane has more than doubled over the last five years, which has significant cost implications. Currently, isoflurane is no longer being used in the majority of Victorian public hospitals with sevoflurane and desflurane remaining as the primary volatile agents. For every one bottle of desflurane used, just over two bottles of sevoflurane are consumed. Despite this, desflurane accounts for more than half of the total volatile agent expenditure. This information allows for the effective planning of cost containment in this area.
